Vitespen (Oncophage), an experimental vaccine, does not prevent renal cell carcinoma (RCC) recurrence or improve survival, researchers reported in The Lancet (2008; published online ahead of print).
In a randomized phase III trial of RCC patients, the combined rate of recurrence and death after a median follow-up of two years was similar among patients who received the vaccine and those managed with observation (37.7% vs. 39.8%).
Continue Reading
No improvement in survival was observed even after an additional 17 months of follow-up.
